Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion: Japan Alteplase Clinical Trial II (J-ACT II)

Stroke

Volumn 41, Issue 3, 2010, Pages 461-465

  Mori, Etsuro ^a   Minematsu, Kazuo ^b   Nakagawara, Jyoji ^c   Yamaguchi, Takenori ^b   Sasaki, Makoto ^d   Hirano, Teruyuki ^e  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c Nakamura Memorial Hospital   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Acute ischemic stroke; Magnetic resonance angiography; Middle cerebral artery occlusion; Recanalization; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RECANALIZATION; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; JAPAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MIDDLE CEREBRAL ARTERY; PROSPECTIVE STUDIES; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77649088870     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.573477     Document Type: Article

References (19)

1. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37: 1810-1815.
2. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasmino-gen activator in acute carotid artery territory stroke. Neurology. 1992;42: 976-982.
3. Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cere-brovasc Dis. 1993;3:269-272.
4. Yamaguchi T, Kikuchi H, Hayakawa T. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, eds. Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer-Verlag; 1995: 223-229.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
6. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973.
7. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, Dunn B, Warach S. Early MRI findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55:105-112.
8. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recom-binant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
9. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992;23:646-652.
10. Derex L, Nighoghossian N, Hermier M, Adeleine P, Berthezene Y, Philippeau F, Honnorat J, Froment JC, Trouillas P. Influence of pre-treatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci. 2004;225:3-9.
11. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehlar J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke 6 hours. Stroke. 2002;33:2438-2445
12. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003-2011.
13. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38:2633-2639.
14. Linfante I, Llinas RH, Selim M, Chaves C, Kumar S, Parker RA, Caplan LR, Schlaug G. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke. 2002;33:2066-2071.
15. Thomassen L, Andreassen UW, Morsund AH, Hordnes J, Maintz C, Smievoll AI, Russell D. Thrombolytic therapy in acute ischaemic stroke. Cerebrovasc Dis. 2002;13:163-167. (Pubitemid 34253017)
16. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4-11.
17. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Lavine SR. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474-480.
18. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, Erila T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kohrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39: 3316-3322.
19. Zangerle A, Kiechl S, Spiegel M, Furtner M, Knoflach M, Werner P, Mair A, Wille G, Schmidauer C, Gautsch K, Gotwald T, Felber S, Poewe W, Willeit J. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology. 2007;68:39-44.